Celldex Therapeutics (CLDX) Cash from Operations (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Cash from Operations of 65600000.0 for Q1 2026, down 20.65% year-over-year from 82672056.37 in Q1 2025, and down 2.59% quarter-over-quarter from 63945000.0 in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Cash from Operations (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 65600000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 20.65% year-over-year to 65600000.0; the TTM figure through Mar 2026 stood at 222173000.0 (down 29.54% YoY), while the FY2025 annual figure was 210945000.0, down 33.7% from the prior year.
- Cash from Operations for Q1 2026 stood at 65600000.0, down from 63945000.0 in the prior quarter.
- The five-year high for Cash from Operations was 18993000.0 in Q3 2023, with the low at 65600000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 32533000.0 (2023), against an average of 37961529.41.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 46.03% in 2023, then sank 191.35% in 2024.
- Celldex Therapeutics' Cash from Operations stood at 21762000.0 in 2022, then plunged by 49.49% to 32533000.0 in 2023, then advanced by 0.18% to 32476000.0 in 2024, then plunged by 96.9% to 63945000.0 in 2025, then decreased by 2.59% to 65600000.0 in 2026.
- Business Quant data shows CLDX's Cash from Operations at 65600000.0 in Q1 2026, 63945000.0 in Q4 2025, and 48623000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | -57.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.40 Mn |
| Mar 31, 2026 | -65.60 Mn |
| Dec 31, 2025 | -63.94 Mn |
| Sep 30, 2025 | -48.63 Mn |
| Jun 30, 2025 | -44.01 Mn |
| Mar 31, 2025 | -54.37 Mn |
| Dec 31, 2024 | -32.48 Mn |
| Sep 30, 2024 | -55.34 Mn |
| Jun 30, 2024 | -29.33 Mn |
| Mar 31, 2024 | -40.64 Mn |
| Dec 31, 2023 | -32.53 Mn |
| Sep 30, 2023 | -18.99 Mn |
| Jun 30, 2023 | -27.20 Mn |
| Mar 31, 2023 | -28.57 Mn |
| Dec 31, 2022 | -21.76 Mn |
| Sep 30, 2022 | -35.19 Mn |
| Jun 30, 2022 | -22.24 Mn |
| Mar 31, 2022 | -24.53 Mn |
| Dec 31, 2021 | -14.52 Mn |
| Sep 30, 2021 | -16.37 Mn |